)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Spero Therapeutics (SPRO) investor relations material
Spero Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Phase 3 PIVOT-PO trial for tebipenem HBr in cUTI met its primary endpoint and was stopped early for efficacy, positioning it as a potential first-in-class oral carbapenem; GSK will handle regulatory filings, aiming for FDA submission in 2H 2025.
Spero is eligible for up to $351M in milestones and tiered royalties from GSK, with $25M upon U.S. regulatory filing; final $23.8M milestone payment received in Q3 2025.
SPR720 program suspended after Phase 2a trial failed to meet its primary endpoint; SPR206 discontinued after strategic reprioritization.
Esther Rajavelu appointed President, CEO, CFO, and Treasurer in May 2025 following leadership transition.
Cost savings from early trial completion are expected to extend the cash runway into 2028.
Financial highlights
Cash and cash equivalents as of June 30, 2025, were $31.2M, with an additional $23.8M milestone payment from GSK received in Q3 2025.
Total revenue for Q2 2025 was $14.2M, up from $10.2M in Q2 2024, mainly due to GSK collaboration revenue.
R&D expenses decreased to $10.7M in Q2 2025 from $23.7M in Q2 2024, reflecting lower clinical trial costs.
G&A expenses rose to $5.9M in Q2 2025 from $5.5M in Q2 2024, attributed to increased personnel, professional services, and retention/severance costs.
Net loss for Q2 2025 was $1.7M, a significant improvement from $17.9M in Q2 2024; diluted net loss per share was $0.03 versus $0.33.
Outlook and guidance
Existing cash and milestone payments from GSK are expected to fund operations and capital expenditures into 2028.
Focus remains on advancing tebipenem HBr through regulatory approval as the primary value driver.
Additional funding may be required beyond 2028 or if operating plans change; options include equity, debt, collaborations, or further cost reductions.
When is FDA action on Tebipenem HBr expected?
What are the next steps for SPR720 program?
What is the company's capital allocation strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Spero Therapeutics earnings date
Q3 202513 Nov, 2025
Next Spero Therapeutics earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Spero Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, including multi-drug-resistant bacterial infections. The company's pipeline includes both oral and intravenous antibiotic candidates designed to address serious and difficult-to-treat infections. Spero's lead programs target conditions such as urinary tract infections and hospital-acquired bacterial infections, with an emphasis on addressing the growing challenge of antibiotic resistance. The company’s research and development efforts aim to provide new therapeutic options in areas with high unmet medical needs. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage